RxDoctor Payments DataLook up a doctor →

Stanley Cohan, MD

Neurology · Portland, ORNPI 1972788644

Payments from drug & device makers

$3,850,046in general payments, 2019–2025

Across 558 payments — averaging $6899.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.1M
  • Biogen$482K
  • F. Hoffmann-la Roche AG$379K
  • AbbVie$347K
  • Genentech, Inc.$297K
  • EMD Serono, Inc.$65K
  • plus $204K from 13 others
$48,190in research payments, 2019–2025

Across 51 payments — averaging $944.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$37K
  • F. Hoffmann-la Roche AG$6K
  • Sanofi-aventis U.S. LLC$4K
  • Sanofi$681

What the payments were for

  • Consulting fees$152,12446%
  • Speaking & faculty fees$152,11346%
  • Travel & lodging$16,4845%
  • Food & beverage$13,1634%
  • Education$1590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,850,046 in reported general payments places this provider in the 95th percentile of 228 neurology providers in Oregon.

See all neurology providers in Oregon

Medicare billing

Part B allowed, 2024
$28,993
Medicare patients
82
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab36$377,250
VumerityDiroximel Fumarate28$300,143
Plegridy PenPeginterferon Beta-1a20$194,244
ZeposiaOzanimod Hydrochloride21$176,485
MayzentSiponimod12$107,173
Avonex (4 Pack)Interferon Beta-1a13$98,645
Teriflunomide16$22,251
MyrbetriqMirabegron17$20,041
NuedextaDextromethorphan Hbr/Quinidine11$19,148
FingolimodFingolimod Hcl45$14,086
Dalfampridine ErDalfampridine89$9,890
Baclofen212$6,308
Gabapentin176$5,675
Dimethyl Fumarate36$5,380
Modafinil54$4,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Avonex (4 Pack)$482,289$398,78841 claims
E.r. Squibb & Sons, L.L.C.Zeposia$35,104$176,48521 claims
NovartisMayzent$2,074,823$107,17312 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$59$50926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 228 neurology providers in Oregon.

Other neurology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →